Michael Henderson, the Chief Executive Officer of Apogee Therapeutics, has executed a stock sale amounting to $1.64 million. This transaction reflects Henderson's decision to divest a portion of his holdings in the company. The sale was conducted in accordance with regulatory requirements and follows the company's recent financial disclosures. Details regarding the specific number of shares sold and the timing of the transaction have not been publicly disclosed.
Related Articles
Don't miss out on breaking stories and in-depth articles.